Skip to Content

Join the 'Soft Tissue Sarcoma' group to help and get support from people like you.

Soft Tissue Sarcoma News

Related terms: Alveolar rhabdomyosarcoma, Cancer, Rhabdomyosarcoma, Cancer, Soft Tissue Sarcoma, Embryonal rhabdomyosarcoma, Sarcoma botryoides

Gene Changes May Put Childhood Cancer Survivors at Risk

Posted 4 Apr 2017 by Drugs.com

MONDAY, April 3, 2017 – Many survivors of childhood cancer have mutations in cancer-associated genes, possibly increasing their risk for cancers later in life, researchers report. The new study included more than 3,000 people who survived childhood cancer for five years or more. More than 12 percent had changes in one of 156 genes linked to increased risk of cancer, the findings showed. By age 45, more than one-quarter of the people had developed another cancer, most commonly meningioma (brain tumor), thyroid cancer, breast cancer and non-melanoma skin cancer, according to the study. The report was scheduled for presentation Monday at an American Association for Cancer Research (AACR) meeting in Washington, D.C. Research presented at medical meetings should be considered preliminary until it is published in a peer-reviewed journal. "The remarkable advances realized over the past four ... Read more

Related support groups: Cancer, Breast Cancer, Basal Cell Carcinoma, Skin Cancer, Squamous Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Tumor, Liposarcoma

Survival Continues to Improve for Most Cancers

Posted 31 Mar 2017 by Drugs.com

FRIDAY, March 31, 2017 – Overall cancer death rates in the United States continue to fall, but racial gaps persist, a new report says. Death rates fell between 2010 and 2014 for 11 of the 16 most common cancers in men and for 13 of the most common types in women, including lung, colon, prostate and breast cancers. However, death rates rose for cancers of the liver, pancreas and brain in men and for the liver and uterus in women. And improvements in cancer survival weren't equal for all Americans. "While this report found that five-year survival for most types of cancer improved among both blacks and whites over the past several decades, racial disparities for many common cancers have persisted, and they may have increased for prostate cancer and female breast cancer," said Dr. Lynne Penberthy. She's associate director of the U.S. National Cancer Institute's Surveillance Research ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Skin Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Osteosarcoma, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Cervical Cancer, Bladder Cancer, Melanoma - Metastatic

Drug Combo Shows Promise Against Some Soft Tissue Tumors

Posted 2 Dec 2016 by Drugs.com

FRIDAY, Dec. 2, 2016 – Using a new cancer drug with an existing one appears to work against soft tissue sarcoma cancers, a new study indicates. These cancers of soft tissues such as fat, muscles, blood vessels, tendons and ligaments are rare, but difficult to treat if they are advanced and have spread to other parts of the body, the researchers said. "Soft tissue sarcomas represent a rare group of malignant tumors. Despite the use of surgery, radiotherapy and chemotherapy to treat the tumor in the localized region in which it started, up to 40 percent of patients will develop recurrence with cancer cells spreading to other parts of the body," said researcher Antoine Italiano. He heads the early phase trials and sarcoma units at Institut Bergonie in Bordeaux, France. His study found that the combination of a new cancer drug called GDC-0575 with the existing cancer drug gemcitabine ... Read more

Related support groups: Cancer, Gemzar, Soft Tissue Sarcoma, Gemcitabine, Dermatofibrosarcoma Protuberans, Liposarcoma, Rhabdomyosarcoma, Kaposi's Sarcoma

FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma

Posted 19 Oct 2016 by Drugs.com

October 19, 2016 – The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment. “For these patients, Lartruvo, added to doxorubicin, provides a new treatment option,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and acting director of the FDA’s Oncology Center of Excellence. “This is the first new therapy approved by the FDA for the initial ... Read more

Related support groups: Cancer, Doxorubicin, Soft Tissue Sarcoma, Lartruvo, Olaratumab

Lartruvo (olaratumab) Approved for Soft-Tissue Cancers

Posted 19 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 19, 2016 – Lartruvo (olaratumab) has been approved by the U.S. Food and Drug Administration to treat adults with certain soft-tissue sarcomas, cancers that develop in areas such as the muscles, fat, blood vessels and tendons. Lartruvo has been sanctioned for use with the chemotherapy drug doxorubicin in cases that cannot be treated with radiation or surgery, the FDA said Wednesday in a news release. More than 12,000 new cases of soft-tissue sarcoma are projected to be diagnosed this year and nearly 5,000 people are likely to die from the disease, the agency said, citing estimates from the U.S. National Cancer Institute. Lartruvo is designed to block cell receptors that fuel tumor growth, the FDA said. The drug was evaluated in clinical trials involving 133 people with soft-tissue carcinomas. Average survival among people who took Lartruvo and doxorubicin was 8.2 months, ... Read more

Related support groups: Cancer, Doxorubicin, Soft Tissue Sarcoma, Adriamycin, Dermatofibrosarcoma Protuberans, Liposarcoma, Adriamycin PFS, Rhabdomyosarcoma, Adriamycin RDF, Kaposi's Sarcoma

Radiation May Help After Surgery for 'Soft-Tissue' Cancers

Posted 15 Apr 2016 by Drugs.com

THURSDAY, April 14, 2016 – Older patients with a type of cancer called soft-tissue sarcomas may benefit more from radiation therapy after surgery than younger patients do, a new study suggests. The results might change the way older patients are treated for soft-tissue sarcomas, which are cancers that develop in muscles, fat and other types of tissue, the study authors said. Surgery is typically used to treat these cancers. But it hasn't been clear if radiation therapy after surgery improved survival. The new study looked at information from more than 15,300 U.S. adults with localized soft-tissue sarcomas. Some were treated with surgery alone, while others had surgery and radiation. Treatments occurred between 1990 and 2011. Radiation after surgery improved survival compared to surgery alone, but this was seen mostly in patients 65 and older, the study showed. "We found that older ... Read more

Related support groups: Cancer, Soft Tissue Sarcoma, History - Radiation Therapy

FDA Approves Halaven (eribulin mesylate) for the Treatment of Liposarcoma

Posted 28 Jan 2016 by Drugs.com

January 28, 2016 – The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug. “Halaven is the first drug approved for patients with liposarcoma that has demonstrated an improvement in survival time,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “The clinical trial data the FDA reviewed indicates that Halaven increased overall survival by approximately seven months, offering patients a clinically meaningful drug.” Soft tissue sarcoma (STS) is a disease in which cancer cells form in the sof ... Read more

Related support groups: Soft Tissue Sarcoma, Eribulin, Liposarcoma, Halaven

FDA Approves Yondelis (trabectedin) for the Treatment of Specific Soft Tissue Sarcomas

Posted 27 Oct 2015 by Drugs.com

October 23, 2015 - The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who previously received chemotherapy that contained anthracycline. According to the National Cancer Institute, STS is a disease in which cancer cells form in the soft tissues of the body, including the muscles, tendons, fat, blood vessels, lymph vessels, nerves and tissues around joints. Liposarcoma and leiomyosarcoma are specific types of STS that occur in fat cells (liposarcoma) or smooth muscle cells (leiomyosarcoma). STS can form almost anywhere in the body, but is most common in the head, neck, arms, legs, trunk and abdomen. In 2014, an estimated 12,000 cases of STS ... Read more

Related support groups: Soft Tissue Sarcoma, Trabectedin, Yondelis

New Drug Yondelis Approved for Soft-Tissue Cancer

Posted 27 Oct 2015 by Drugs.com

FRIDAY, Oct. 23, 2015 – The chemotherapy drug Yondelis (trabectedin) has been approved by the U.S. Food and Drug Administration to treat certain soft-tissue sarcomas (STS) that have spread or can't be treated by surgery. STS can form anywhere, but most often affects soft tissues in the head, neck, arms, legs, trunk and abdomen, the agency said Friday in a news release. Some 12,000 cases were diagnosed in the United States last year. Yondelis is approved for people with two forms of STS – liposarcoma or leiomyosarcoma – who have had previous treatment with chemotherapy that contained the drug anthracycline, the FDA said. Yondelis was evaluated in clinical studies involving 518 people. People who took Yondelis had cancer progression stopped for an average of 4.2 months, compared to an average of 1.5 months among those who took another anti-cancer drug, the agency said. The most common ... Read more

Related support groups: Soft Tissue Sarcoma, Trabectedin, Yondelis

Young Cancer Survivors Often Develop New Malignancies

Posted 6 Oct 2015 by Drugs.com

TUESDAY, Oct. 6, 2015 – Teen and young adult cancer survivors are at increased risk for other cancers later in life, a new study reveals. Researchers analyzed U.S. National Cancer Institute data on people who survived cancers before age 40. They had the most common types of cancers in that age group: leukemia, lymphoma, testicular, ovarian, thyroid, breast, soft tissue and bone cancers. "This is a patient demographic that has been largely overlooked," said senior study author Dr. Robert Goldsby, a professor of pediatrics at the University of California, San Francisco Benioff Children's Hospital. Over 30 years, nearly 14 percent of the survivors were diagnosed with another, different type of cancer. On average, the second cancer occurred within 15 years. Compared to people in the general population, patients successfully treated for cancer between ages 15 and 39 were nearly 60 percent ... Read more

Related support groups: Cancer, Breast Cancer, Hairy Cell Leukemia, Leukemia, Chronic Myelogenous Leukemia (CML), Basal Cell Carcinoma, Lymphoma, Melanoma, Skin Cancer, Chronic Lymphocytic Leukemia (CLL), Ovarian Cancer, Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Stomach Cancer, Acute Lymphoblastic Leukemia, Cutaneous T-cell Lymphoma, Hodgkin's Lymphoma, Soft Tissue Sarcoma, Testicular Cancer, Acute Lymphocytic Leukemia

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Rituxan, Isotretinoin, Lung Cancer, Renal Cell Carcinoma

Experimental Treatment for Rare Soft-Tissue Cancer Shows Promise in Mice

Posted 30 Dec 2013 by Drugs.com

MONDAY, Dec. 30, 2013 – Blocking a key protein involved in the growth of a rare, incurable type of soft-tissue cancer may eliminate the disease, according to a new study involving mice. Researchers from UT Southwestern found that inhibiting the action of a protein, known as BRD4, caused cancer cells in malignant peripheral nerve sheath tumors to die. Malignant peripheral nerve sheath tumors are highly aggressive soft-tissue cancers, or sarcomas, that form around nerves. "This study identifies a potential new therapeutic target to combat [malignant peripheral nerve sheath tumor], an incurable type of cancer that is typically fatal," study senior author Dr. Lu Le, an assistant professor of dermatology, said in a university news release. "The findings also provide important insight into what causes these tumors to develop." The findings were published online Dec. 26 in the journal Cell ... Read more

Related support groups: Soft Tissue Sarcoma

Votrient Approved to Treat Cancer That Begins in Soft Tissue

Posted 27 Apr 2012 by Drugs.com

FRIDAY, April 27 – Votrient (pazopanib) has been approved by the U.S. Food and Drug Administration to treat people with soft tissue sarcoma that have received previous chemotherapy. This type of tumor originates in soft tissue such as a muscle, fat, or fibrous tissue, the agency said in a news release. About 10,000 cases of soft tissue sarcoma are reported each year in the United States. Votrient works by inhibiting angiogenisis, the production of new blood vessels that fuel tumor growth. The drug's safety and effectiveness were evaluated in clinical studies involving 369 people with soft tissue sarcoma who had undergone chemotherapy. Among people who took Votrient, the disease didn't progress for an average of 4.6 months, compared to 1.6 months among people who took an inactive placebo. The most common side effects of Votrient included fatigue, diarrhea, nausea, weight loss, high ... Read more

Related support groups: Votrient, Pazopanib, Soft Tissue Sarcoma

FDA Approves Votrient for Advanced Soft Tissue Sarcoma

Posted 26 Apr 2012 by Drugs.com

April 26, 2012 – The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues. Votrient is a pill that works by interfering with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. A rare cancer with many subtypes, soft tissue sarcoma occurs in about 10,000 cases annually in the United States. More than 20 subtypes of sarcoma were included in the clinical trial leading to approval of Votrient. The drug is not approved for patients with adipocytic soft tissue sarcoma and gastrointestinal stromal tumors. "Soft tissue sarcomas are a diverse group of tumors and the approval of Votrient for this general class of tumors is the first in decades," ... Read more

Related support groups: Votrient, Pazopanib, Soft Tissue Sarcoma

Cancer Patients Should Ask Doctors to Use Simple Terms

Posted 28 Sep 2011 by Drugs.com

WEDNESDAY, Sept. 28 – Cancer patients are often faced with many difficult-to-understand treatment choices that can have serious side effects and even mean the difference between life and death. That's why it's crucial that patients insist doctors use plain language in explaining the options, advised Angela Fagerlin, an associate professor of internal medicine at the University of Michigan Medical School and a researcher at the U-M Comprehensive Cancer Center. "People are making life and death decisions that may affect their survival and they need to know what they're getting themselves into. Cancer treatments and tests can be serious. Patients need to know what kind of side effects they might experience as a result of the treatment they undergo," Fagerlin said in a university news release. She and her colleagues outlined a number of tips to help patients get the information they need ... Read more

Related support groups: Cancer, Depo-Provera, Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Gleevec, Rituxan, Isotretinoin, Lung Cancer, Renal Cell Carcinoma

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Kaposi's Sarcoma, Rhabdomyosarcoma, Dermatofibrosarcoma Protuberans, Liposarcoma, Cancer

Related Drug Support Groups

methotrexate, Votrient, pazopanib, doxorubicin, Adriamycin, Lartruvo, trabectedin, olaratumab, Adriamycin RDF, Adriamycin PFS, Yondelis